Narin Nasiroglu IMGA, Serhat IŞIK, Mehtap Navdar BAŞARAN, Bercem Aycicek DOGAN, Mazhar Müslüm TUNA, Mustafa ÜNAL, DİLEK BERKER, Serdar GÜLER

Predictivity of stimulated serum thyroglobulin and antithyroglobulin antibodies for the efficacy of thyroid remnant ablation on patients with differentiated thyroid carcinoma

Differentiated thyroid cancers (DTC) are the most frequently occuring endocrine malignancies and accounts for >= 90% of all thyroid cancers. It was suggested that after total or near total thyroidectomy, the stimulated thyroglobuline (sTg) and quantified uptake in whole body scintigraphy (WBS) are significant predictors for the successful ablation and disease-free status. We aimed to evaluate preablative thyroid stimulating hormone (TSH), sTg and anti-thyroglobulin antibodies (TgAbs) levels, after following thyroid hormone withdrawal, and compare them with diagnostic WBS (DxWBS) uptake for predict the efficacy of radioiodine (RAI) ablation therapy in DTC patients. We retrospectively investigated 100 consecutively patients which followed up for DTC in Ankara Numune Education and Research Hospital at Department of Endocrinology and Metabolism between January 2006 and June 2013. Patients had histologically confirmed DTC and underwent RAI remnant ablation therapy without clinical or radiological evidence of distant metastases. 131I was used generally from 30-200 mCi dosage in all 100 patients. (median dose, 100 mCi). Preablation TSH, preablation sTg, postablation TSH, postablation sTg, postablation TgAbs levels, tumor size and tumor multifocality did not differ between DxWBS uptake negative and positive groups, while the preablation TgAbs level was found significantly lower in DxWBS uptake negative group (p<0.001). The cut-off value of preablation Tg for predicting postablation WBS uptake was found 0.31 ng/mL with 67.4% sensitivity and 54.5% specificity. After RAI remnant ablation therapy, postablation WBS and DxWBS, are useful for follow up patients with high or intermediate risk of persistent disease. We found that preablation TgAbs positivity can effect the postablation WBS and DxWBS uptake in DTC patients

PDF

___

Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012;2012:618985.

Institute, National Cancer; Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Factsheets. Thyroid Cancer. Bethesda, MD: National Cancer Institute; 2014

Lebastchi AH, Callender GG. Thyroid cancer. Curr Probl Cancer. 2014;38(2):48-74.

Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-63.

Lim I, Kim SK, Hwang SS, Kim SW, Chung KW, Kang HS, Lee ES. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer. Ann Nucl Med. 2012;26(10):777-86.

Hollowell JG, Staehling NW, Hannon WH, Gunter EW, Spencer CA, Braverman LE Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): NHANES III. J Clin Endocrinol Metab. 2002;87(2):489-99.

Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9(5):435-4.

Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2013;90(10):5566-75.

Gorges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, Janssen OE. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153(1):49-55.

Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97(1):90-6.

Bernier MO. Morel O. Rodien P. Muratet JP. Giraud P. Rohmer V. Jeanguillaume C. Bigorgne JC. Jallet P. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2005;32(12):1418-21.

Tenenbaum F, Corone C, Schlumberger M, Parmentier C. Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer. 1996;32A(7):1262.

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS. Doherty GM. Haugen BR. Hauger BR. Kloos RT. Lee SL. Mandel SJ. Mazzaferri EL. McIver B. Pacini F. Schlumberger M. Sherman SI. Steward DL. Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.

Eustatia-Rutten CF. Smit JW. Romijn JA. van der Kleij- Corssmit EP. Pereira AM. Stokkel MP. Kievit J. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma. a structured meta-analysis. Clin Endocrinol (Oxf). 2004;61(6):61-74.

Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, Burch HB. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97(8):2754-63.

Lee HJ1, Rha SY, Jo YS, Kim SM, Ku BJ, Shong M, Kim YK, Ro HK. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. Am J Clin Oncol. 2007;30(1):63-8.

Pelttari H, Valimaki MJ, Loyttyniemi E, Schalin-Jantti C. Post- ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol. 2010;163:757-63.

Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, Burch HB The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97:2754-63.

Tamilia M, Al-Kahtani N, Rochon L, Hier MP, Payne RJ, Holcroft CA, Black MJ 2011 Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun. 32:212-220.

Giovanella L, Suriano S, Ceriani L, Verburg FA. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clin Nucl Med. 2011;36:109-12.

Bachelot A, Leboulleux S, Baudin E, Hartl DM, Caillou B, Travagli JP, Schlumberger M. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf). 2005;62:376-9.

Tsushima Y, Miyauchi A, Ito Y, Kudo T, Masuoka H, Yabuta T, Fukushima M, Kihara M, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Kikumori T, Imai T, Kiuchi T. Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thy- roidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients. Endocr J. 2013;60(7):871-6.

Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol. 2002;57(2):215-21.

Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93(12):4683-9.